Investigational drug · Phase 3
Zuberitamab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Membranous Nephropathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
13
Any phase or sponsor naming "Zuberitamab"
First trial start
2024
Nov 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zuberitamab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Membranous Nephropathy
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Zuberitamab" as an intervention, largest first.
- Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous NephropathyPivotal-lookingNot yet recruiting
BioRay Pharmaceutical Co., Ltd.Industry
NCT07830433 · 150 participants (planned) · Start Oct 2026 · Primary completion Dec 2029
Drug: Zuberitamab 1000mg; Cyclosporine · For: Primary Membranous Nephropathy
Sites: Shanghai, China
- A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyPivotal-lookingActive, not recruiting
BioRay Pharmaceutical Co., Ltd.Industry
NCT06642909 · 135 participants (planned) · Start Nov 13, 2024 · Primary completion Mar 31, 2027
Drug: Zuberitamab 600mg; Zuberitamab 1000mg and 1 more · For: Primary Membranous Nephropathy
Sites: Shanghai, China
- Zuberitamab in the First Episode of Paediatric Nephrotic SyndromePivotal-lookingNot yet recruiting
Children's Hospital of Fudan UniversityAcademic, hospital or other
NCT07765914 · 120 participants (planned) · Start Aug 20, 2026 · Primary completion Aug 20, 2028
Drug: Zuberitamab; standard corticosteroid treatment · For: Nephrotic Syndrome
Sites: Shanghai, China; Changsha, China; Guiyang, China · 9 sites in all
- Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell LymphomaNot yet recruiting
Ou Bai, MD/PHDAcademic, hospital or other
NCT07677813 · 66 participants (planned) · Start Jun 16, 2026 · Primary completion Dec 31, 2029
Drug: R-CHOP+Orelabrutinib; POLA-R-CHP+orelabrutinib and 8 more · For: DLBCL - Diffuse Large B Cell Lymphoma
Sites: Changchun, China
- Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZLActive, not recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07480863 · 65 participants (planned) · Start Oct 1, 2025 · Primary completion Oct 1, 2029
Drug: Orelabrutinib; Zuberitamab and 3 more · For: Marginal Zone Lymphoma(MZL)
Sites: Beijing, China
- Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular LymphomaNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT06757894 · 50 participants (planned) · Start Feb 1, 2025 · Primary completion Feb 1, 2028
Drug: Zuberitamab; Bendamustine · For: Follicular Lymphoma (FL)
Sites: Guangzhou, China
- Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaNot yet recruiting
Li ZhimingAcademic, hospital or other
NCT07231250 · 40 participants (planned) · Start Jan 15, 2026 · Primary completion Sep 15, 2026
Drug: Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone · For: DLBCL - Diffuse Large B Cell Lymphoma; Chemo-free Therapy; Bispecific Antibody
Sites: Guangzhou, China
- BR Combined With OR in Treatment-naïve Marginal Zone LymphomaNot yet recruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT07008053 · 37 participants (planned) · Start Jul 2025 · Primary completion Jul 2027
Drug: BR+OR · For: Marginal Zone Lymphomas
Sites: Fuzhou, China; Shijiazhuang, China; Changsha, China · 6 sites in all
Peking University Third HospitalAcademic, hospital or other
NCT07257510 · 34 participants (planned) · Start Aug 1, 2025 · Primary completion Aug 1, 2028
Drug: Pomalidomide; Orelabrutinib and 2 more · For: Mantle Cell Lymphoma (MCL); POZ
Sites: Beijing, China
Li ZhimingAcademic, hospital or other
NCT06985472 · 33 participants (planned) · Start Nov 13, 2024 · Primary completion Dec 1, 2025
Drug: ZO · For: Initial MZL; Untreated MZL; BTKi and 1 more
Sites: Guangzhou, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Primary thyroid lymphoma with Hashimoto's thyroiditis: A case report and literature review.
Liu F, Xin X, Tan K, et al. · Oncol Lett 2026
- Case Report: A case of type II cryoglobulinemia secondary to diffuse large B-cell lymphoma.
Mao C, Hao X · Front Oncol 2026
- Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study.
Zong L, Wang S, Zhao K, et al. · Front Immunol 2025
- First-line and Second-line Therapy of Zuberitamab in Idiopathic Membranous Nephropathy: A Single-center Retrospective Study.
Wang L, Yang M, Yan L, et al. · Kidney Med 2026
- Cost-Effectiveness of First-Line Zuberitamab-CHOP versus Rituximab-CHOP Regimens in Untreated CD20+ Diffuse Large B-Cell Lymphoma in China.
Gao L, Zhu H, Wang J, et al. · Risk Manag Healthc Policy 2025
- Case Report: Severe Pneumocystis jirovecii pneumonia following zuberitamab treatment in autoimmune hemolytic anemia.
Yang Q, Ding P, Liu YX, et al. · Front Immunol 2025
Also in development for Primary Membranous Nephropathy
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- B007Phase 33 trials
Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis
- CyclosporinPhase 32 trials
Shanghai JMT-Bio Inc. · Primary Membranous Nephropathy
- SHR-2173Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy
- BudoprutugTNT119Phase 23 trials
Climb Bio, Inc. · Primary Membranous Nephropathy, Systemic Lupus Erthematosus, Immune Thrombocytopenia (ITP)
- FKC289Phase 22 trials
Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Primary Membranous Nephropathy, Primary Light Chain (AL) Amyloidosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.